MX376202B - Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. - Google Patents

Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.

Info

Publication number
MX376202B
MX376202B MX2019001781A MX2019001781A MX376202B MX 376202 B MX376202 B MX 376202B MX 2019001781 A MX2019001781 A MX 2019001781A MX 2019001781 A MX2019001781 A MX 2019001781A MX 376202 B MX376202 B MX 376202B
Authority
MX
Mexico
Prior art keywords
napi
derivatives useful
thiophene derivatives
condensed thiophene
iib
Prior art date
Application number
MX2019001781A
Other languages
English (en)
Other versions
MX2019001781A (es
Inventor
Dariusz Stanislaw Wodka
David Andrew Coates
Jeffrey Alan Peterson
Jeffrey Michael Schkeryantz
Ii John Rowley Wetterau
Kevin Robert Fales
Matthew John Valli
Quanrog Shen
Yangping Xu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019001781A publication Critical patent/MX2019001781A/es
Publication of MX376202B publication Critical patent/MX376202B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención proporciona compuestos de la fórmula: (A), sales farmacéuticamente aceptables, composiciones farmacéuticas de estos y métodos para usar estos compuestos, sales o composiciones para tratar la hiperfosfatemia, la enfermedad renal crónica y/o la enfermedad cardiovascular asociada con la enfermedad renal crónica. (ver Fórmula).
MX2019001781A 2016-08-15 2017-08-08 Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. MX376202B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662375169P 2016-08-15 2016-08-15
PCT/US2017/045843 WO2018034883A1 (en) 2016-08-15 2017-08-08 Condensed thiophene derivatives useful as napi-iib inhibitors

Publications (2)

Publication Number Publication Date
MX2019001781A MX2019001781A (es) 2019-07-04
MX376202B true MX376202B (es) 2025-03-07

Family

ID=59677343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001781A MX376202B (es) 2016-08-15 2017-08-08 Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.

Country Status (23)

Country Link
US (1) US10934280B2 (es)
EP (1) EP3497091B1 (es)
JP (1) JP6653410B2 (es)
KR (1) KR102266143B1 (es)
CN (1) CN109563070B (es)
AU (1) AU2017312783B2 (es)
CA (1) CA3033628C (es)
CY (1) CY1123576T1 (es)
DK (1) DK3497091T3 (es)
EA (1) EA037376B1 (es)
ES (1) ES2830444T3 (es)
HR (1) HRP20202025T1 (es)
HU (1) HUE052351T2 (es)
IL (1) IL264785B (es)
LT (1) LT3497091T (es)
MX (1) MX376202B (es)
PL (1) PL3497091T3 (es)
PT (1) PT3497091T (es)
RS (1) RS61165B1 (es)
SA (1) SA519401049B1 (es)
SI (1) SI3497091T1 (es)
WO (1) WO2018034883A1 (es)
ZA (1) ZA201900305B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120388A1 (en) * 2018-11-19 2020-05-28 11949098 Canada Inc. Modulators of rar related orphan receptors (rors)
ES2927100T3 (es) 2019-05-16 2022-11-02 Lilly Co Eli Compuestos inhibidores del intercambiador de sodio-hidrógeno 3
WO2022020714A1 (en) * 2020-07-24 2022-01-27 Inipharm, Inc. Thiophene hsd17b13 inhibitors and uses thereof
EP4244210A4 (en) 2020-11-13 2024-10-30 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof
US12617772B2 (en) 2021-04-05 2026-05-05 Inipharm, Inc. Hydroxypyridine HSD17B13 inhibitors and uses thereof
CA3221186A1 (en) 2021-06-08 2022-12-15 Kenichi Sakai Formulation containing dihydropyridazine-3,5-dione derivative
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2023219127A1 (ja) * 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565190B1 (en) * 2010-04-28 2015-06-03 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
CN103906741B (zh) * 2011-10-27 2016-01-20 安斯泰来制药株式会社 氨烷基取代的n-噻吩基苯甲酰胺衍生物
WO2014003153A1 (ja) * 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
CN105658635B (zh) * 2014-08-22 2019-03-08 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US20200031813A1 (en) 2020-01-30
EA201990095A1 (ru) 2019-07-31
KR102266143B1 (ko) 2021-06-17
RS61165B1 (sr) 2021-01-29
KR20190026895A (ko) 2019-03-13
CA3033628A1 (en) 2018-02-22
HRP20202025T1 (hr) 2021-02-19
PT3497091T (pt) 2020-11-30
AU2017312783B2 (en) 2020-02-06
ES2830444T3 (es) 2021-06-03
SA519401049B1 (ar) 2021-07-14
CA3033628C (en) 2021-01-12
MX2019001781A (es) 2019-07-04
PL3497091T3 (pl) 2021-02-08
AU2017312783A1 (en) 2019-01-24
US10934280B2 (en) 2021-03-02
JP6653410B2 (ja) 2020-02-26
CY1123576T1 (el) 2022-03-24
CN109563070A (zh) 2019-04-02
BR112019000929A2 (pt) 2019-07-09
CN109563070B (zh) 2021-02-26
LT3497091T (lt) 2020-12-28
HUE052351T2 (hu) 2021-04-28
NZ750153A (en) 2021-01-29
EA037376B1 (ru) 2021-03-22
ZA201900305B (en) 2020-12-23
WO2018034883A1 (en) 2018-02-22
EP3497091B1 (en) 2020-10-07
DK3497091T3 (da) 2020-10-19
IL264785B (en) 2021-04-29
JP2019527734A (ja) 2019-10-03
EP3497091A1 (en) 2019-06-19
SI3497091T1 (sl) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EA033061B1 (ru) Спироциклогептаны как ингибиторы rock
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
MY197698A (en) Oxysterols and methods of use thereof
EA201990095A1 (ru) КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
JOP20200086B1 (ar) مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات لـ pi3k-جاما
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201490161A1 (ru) Соединения - ингибиторы сигналинга, опосредуемого рецептором notch
PH12016501462A1 (en) Neprilysin inhibitors
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
WO2015001541A3 (en) Pharmaceutical film composition
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.

Legal Events

Date Code Title Description
FG Grant or registration